ImmuPharma says it welcomes 'helpful' FDA recommendations ahead of phase III study
Lupuzor, also known as P140, is being taken through a final-stage study by ImmuPharma’s American partner Avion Pharmaceuticals
Company
ImmuPharma PLC
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
306 stories · page 4 of 16
ImmuPharma says its US partner for Lupuzor has received a written response from the US FDA to its Type C meeting
The company said the FDA response was detailed and included significant guidance on next steps for the clinical programme
ImmuPharma raising £1.1mln to aid its R&D effort
The drug developer also unveiled a broker option to raise an additional £1.3mln
ImmuPharma hails quick response from FDA for Lupuzor planning meeting
The agreed date from the FDA for providing its written responses is 29 August 2022
ImmuPharma partner makes final preparations for phase III trial
Avion Pharmaceuticals has a licence and development agreement in the States for Lupuzor, also known as P140
ImmuPharma says it is in talks with partners for key assets as it hails progress made last year
It is in discussion with potential non-US licensees for its key asset Lupuzor, with its early-stage anti-infective also attracting attention
ImmuPharma says phase III trial preparations are underway
The clinical evaluation of Lupuzor will be overseen by the company’s US partner, Avion Pharmaceuticals
ImmuPharma drug clears a significant hurdle
Researchers have successfully completed a pharmacokinetic of the company's lead asset
ImmuPharma expects readout from pharmacokinetic by the end of the current quarter
The PK evaluation is part of the new, optimised international phase III trial of Lupuzor in patients with lupus, a condition where the immune system attacks the body’s own tissue and organs
ImmuPharma raises £3.55mln at a significant premium to Friday's share price
The cash injection will be used to fund research and development
ImmuPharma inks two-year collaboration agreement with Imperial College London
Chief operating officer, Dr Tim Franklin, said: "We are all extremely excited to be working with such a world-leading academic institute."
ImmuPharma says partnering discussions 'ongoing' for adaptations of lead asset
P140 is proving to be a platform technology rather than a single treatment
ImmuPharma says Lupozor inventor Sylviane Muller awarded Legion d’honneur
Lupuzor is being developed for the treatment of the autoimmune disease Lupus
ImmuPharma aims to save £1.1m per year in corporate rejig; lead asset prepares for further trials
The update follows a recent streamlining of the company’s board and management
Archive
Proactive headlines: ImmuPharma, Keywords Studios, Conroy Gold…
A look at some of today's main headlines from the Proactive newswire
ImmuPharma lupus drug to undergo pharmacokinetic study after FDA green light
The evaluation will take eight-to-12 weeks to complete
ImmuPharma bids farewell to CEO in boardroom re-shuffle
After 16 years with the company, Dimitri Dimitriou is handing over the reins to chairman Tim McCarthy
ImmuPharma appoints chief operating officer to the board
Dr Tim Franklin has been with the company for three years
ImmuPharma partner makes headway with US FDA
Avion Pharmaceuticals has been granted what’s called a Type C meeting with the Food & Drug Administration
ImmuPharma says international phase III trial remains on track to begin in the second half
The update followed guidance proffered by the US regulator after its meeting with Avion Pharmaceuticals in December, which is leading the development of ImmuPharma's lupus drug